Leavdo

Leavdo Indications/Uses

lenalidomide

Manufacturer:

TTY Biopharm

Distributor:

American Taiwan Biopharm

Marketer:

American Taiwan Biopharm
Full Prescribing Info
Indications/Uses
Multiple myeloma: Leavdo as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Leavdo as combination therapy (see Dosage & Administration) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.
Leavdo in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Myelodysplastic syndromes: Leavdo as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
Mantle cell lymphoma: Leavdo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see Precautions and Pharmacology: Pharmacodynamics under Actions).
Follicular lymphoma: Leavdo in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in